An Ava 1 polymorphism in the TP53 gene

Molecular and Cellular Probes

Volumn 13, Issue 5, 1999, Pages 393-395

  Graziani, D ^a   Romagnoli, S ^a   Cassani, B ^a   Alfano, R M ^a   Roncalli, M ^b   Coggi, G ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

Author keywords

Ava 1 polymorphism; p53 gene polymorphism; p53 intron 9; RFLP; SSCP

Indexed keywords

ALLELE; ARTICLE; BLOOD DONOR; CANCER GENETICS; CONTROLLED STUDY; DNA POLYMORPHISM; EXON; GENE LOSS; GENETIC CONSERVATION; HUMAN; HUMAN CELL; INTRON; ITALY; MALIGNANT TRANSFORMATION; NORMAL HUMAN; POINT MUTATION; PRIORITY JOURNAL; RESTRICTION SITE; RNA SPLICING; TUMOR GROWTH; FEMALE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENETICS; MALE; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SINGLE STRAND CONFORMATION POLYMORPHISM; TUMOR SUPPRESSOR GENE;

RESTRICTION ENDONUCLEASE;

BLOOD DONORS; DNA RESTRICTION ENZYMES; EXONS; FEMALE; GENE FREQUENCY; GENES, P53; HUMANS; INTRONS; ITALY; MALE; POINT MUTATION; POLYMORPHISM, GENETIC; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL;

EID: 0032589343     PISSN: 08908508     EISSN: None     Source Type: Journal    
DOI: 10.1006/mcpr.1999.0256     Document Type: Article

References (15)

1. Levine A. J, Momand J, Finlay C. A. The p53 tumor suppressor gene. Nature. 351:1991;453-456.
2. Hollstein M, Sidransky D, Vogelstein B, Harris C. C. p53 mutation in human cancers. Science. 253:1991;49-53.
3. Hainaut P, Hernandez T, Robinson A. IARC database of p53 gene mutations in human tumors and cell lines: updated compilation, revised formats and new visualization tools. Nucleic Acid Research. 26:1998;205-213.
4. Fearon E. R, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell. 61:1990;759-767.
5. Greenblatt M. S, Bennet W. P, Hollstein M, Harris C. C. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Research. 54:1994;4855-4878.
6. Levesque M. A, Katsaros D, Yu H, Zola P, Sismondi P, Giardina G, Diamandis E. P. Mutant p53 protein overexpression is associated with poor outcome in patients with well or moderately differentiated ovarian carcinoma. Cancer. 75:1995;1327-1338.
7. Nabeya Y, Loganzo F, Maslak P. The mutational status of p53 protein in gastric and esophageal adenocarcinoma cell lines predicts sensitivity to chemotherapeutic agents. International Journal of Cancer. 64:1995;37-46.
8. Righetti S. C, Della Torre G, Pilotti S. A comparative study of p53 gene mutation, protein accumulation, response to cisplatin-based chemotherapy in advanced ovarian carcinoma. Cancer Research. 56:1996;689-693.
9. Carbone D, Chiba I, Mitsudomi T. Polymorphism at codon 213 within the p53 gene. Oncogene. 6:1991;1691-1692.
10. Mazars G. R, Jeanteur P, Lynch H. T, Lenoir G, Theillet C. Nucleotide sequence polymorphism in a hotspot mutation region of the p53 gene. Oncogene. 7:1992;781-782.
11. Felix C. A, Brown D. L, Mitsudomi T. Polymorphism at codon 36 of the p53 gene. Oncogene. 9:1994;327-328.
12. Oliva M. R, Saez G. T, Latres E, Cordon-Cardo C. A new polymorphic site in intron 2 of TP53 characterizes LOH in human tumors by PCR-SSCP. Diagnostic Molecular Pathology. 4:1995;54-58.
13. Ito T, Seyama T, Hayashi T. HaeIII polymorphism in intron 1 of the human p53 gene. Human Genetics. 93:1994;222.
14. Marchetti A, Buttitta F, Merlo G. p53 alteration in non-small cell lung cancers correlate with metastatic involvement of hilar and mediastinal lymph nodes. Cancer Research. 53:1993;2846-2851.
15. Bosari S, Marchetti A, Buttitta F. Detection of p53 mutations by Single-Strand Conformation Polymorphisms (SSCP) gel electrophoresis. A comparative study of radioactive and nonradioactive Silver-stained SSCP analysis. Diagnostic Molecular Pathology. 4:1995;249-255.